{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:12:46Z","timestamp":1793686366935,"version":"4.5.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Inflammation is a strong driver of atherosclerotic cardiovascular disease (ASCVD). There is a large unmet need for therapies that prevent or reduce excessive inflammation while avoiding systemic immunosuppression. We showed previously that selective inhibition of pro-inflammatory interleukin-6 (IL-6) trans-signalling by the fusion protein olamkicept (sgp130Fc) prevented and reduced experimental murine atherosclerosis in low-density lipoprotein receptor-deficient (<jats:italic>Ldlr<\/jats:italic><jats:sup>\u2212\/\u2212<\/jats:sup>) mice on a high-fat, high-cholesterol diet independently of low-density lipoprotein (LDL) cholesterol metabolism. Therefore, we allowed compassionate use of olamkicept (600\u00a0mg intravenously biweekly for 10\u00a0weeks) in a patient with very-high-risk ASCVD. Despite optimal LDL cholesterol under maximum tolerated lipid-lowering treatment, the patient had a remaining very high risk for future cardiovascular events related to significant arterial wall inflammation with lipoprotein (a) [Lp(a)]-cholesterol as the main contributor. <jats:sup>18<\/jats:sup>Fluorodeoxyglucose positron emission tomography\/computed tomography (<jats:sup>18<\/jats:sup>FDG PET\/CT) measurements were performed before and after the treatment period. Olamkicept reduced arterial wall inflammation in this patient without interfering with lipoprotein metabolism. No clinical or laboratory side effects were observed during or after treatment with olamkicept. Our findings in this patient matched the results from our mechanistic study in <jats:italic>Ldlr<\/jats:italic><jats:sup>\u2212\/\u2212<\/jats:sup> mice, which were extended by additional analyses on vascular inflammation. Olamkicept may be a promising option for treating ASCVD independently of LDL cholesterol metabolism. A Phase II trial of olamkicept in ASCVD is currently being prepared.<\/jats:p>","DOI":"10.3389\/fphar.2022.758233","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T06:52:12Z","timestamp":1654757532000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Case Report: Arterial Wall Inflammation in Atherosclerotic Cardiovascular Disease is Reduced by Olamkicept (sgp130Fc)"],"prefix":"10.3389","volume":"13","author":[{"given":"Dominik M.","family":"Schulte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg H.","family":"Waetzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Schuett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berenice","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Garbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Lokau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Kathrin","family":"Vlacil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"Seoudy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Schieffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Rosenstiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Seeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Laudes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Rose-John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"L\u00fctzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Grote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1161\/ATVBAHA.119.311998","article-title":"Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk","volume":"39","author":"Ait-Oufella","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3389\/fcvm.2017.00084","article-title":"An Interleukin-6 Receptor Antibody Suppresses Atherosclerosis in Atherogenic Mice","volume":"4","author":"Akita","year":"2017","journal-title":"Front. Cardiovasc Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.nic.2015.09.004","article-title":"FDG PET\/CT Imaging of Carotid Atherosclerosis","volume":"26","author":"Ali","year":"2016","journal-title":"Neuroimaging Clin. N. Am."},{"key":"B4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41467-020-20303-z","article-title":"Hepatocyte-specific IL11 Cis-Signaling Drives Lipotoxicity and Underlies the Transition from NAFLD to NASH","volume":"12","author":"Dong","year":"2021","journal-title":"Nat. Commun."},{"key":"B5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nrd.2018.45","article-title":"Interleukin-6: Designing Specific Therapeutics for a Complex Cytokine","volume":"17","author":"Garbers","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"B6","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jacbts.2021.01.013","article-title":"Selective Interleukin-6 Trans-signaling Blockade Is More Effective Than Panantagonism in Reperfused Myocardial Infarction","volume":"6","author":"George","year":"2021","journal-title":"JACC Basic Transl. Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"703","DOI":"10.4049\/jimmunol.1201044","article-title":"IL-6 Controls the Innate Immune Response against Listeria Monocytogenes via Classical IL-6 Signaling","volume":"190","author":"Hoge","year":"2013","journal-title":"J. Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1016\/j.jacc.2018.09.038","article-title":"IL-1\u03b2 Inhibition Reduces Atherosclerotic Inflammation in HIV\u00a0Infection","volume":"72","author":"Hsue","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s12350-018-1289-5","article-title":"Imaging Inflammation in Atherosclerotic Plaques: Just Make it Easy!","volume":"26","author":"Hyafil","year":"2019","journal-title":"J. Nucl. Cardiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1046\/j.1432-1327.2001.01867.x","article-title":"Soluble Gp130 Is the Natural Inhibitor of Soluble Interleukin-6 Receptor Transsignaling Responses","volume":"268","author":"Jostock","year":"2001","journal-title":"Eur. J. Biochem."},{"key":"B11","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/eurheartj\/eht367","article-title":"Inflammatory Cytokines and Risk of Coronary Heart Disease: New Prospective Study and Updated Meta-Analysis","volume":"35","author":"Kaptoge","year":"2014","journal-title":"Eur. Heart J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1016\/j.jacc.2017.09.028","article-title":"Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond","volume":"70","author":"Libby","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12876-020-1165-z","article-title":"Proportion of NAFLD Patients with Normal ALT Value in Overall NAFLD Patients: a Systematic Review and Meta-Analysis","volume":"20","author":"Ma","year":"2020","journal-title":"BMC Gastroenterol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.atherosclerosis.2007.02.023","article-title":"Atheroprotective Role of Interleukin-6 in Diet- And\/or Pathogen-Associated Atherosclerosis Using an ApoE Heterozygote Murine Model","volume":"197","author":"Madan","year":"2008","journal-title":"Atherosclerosis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.atherosclerosis.2015.04.014","article-title":"Circulating Levels of Interleukin 6 Soluble Receptor and its Natural Antagonist, Sgp130, and the Risk of Myocardial Infarction","volume":"240","author":"Moreno Vel\u00e1squez","year":"2015","journal-title":"Atherosclerosis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3389\/fcvm.2019.00090","article-title":"New Promises and Challenges on Inflammation and Atherosclerosis: Insights From CANTOS and CIRT Trials","volume":"6","author":"Palmer","year":"2019","journal-title":"Front. Cardiovasc Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.atherosclerosissup.2017.05.004","article-title":"Specific Lp(a) Apheresis: A Tool to Prove Lipoprotein(a) Atherogenicity","volume":"30","author":"Pokrovsky","year":"2017","journal-title":"Atheroscler. Suppl."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1001\/jamacardio.2020.2413","article-title":"Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial","volume":"5","author":"Puri","year":"2020","journal-title":"JAMA Cardiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-Dose Methotrexate for the Prevention of Atherosclerotic Events","volume":"380","author":"Ridker","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream to Identify Novel Targets for Atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ. Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1161\/CIRCRESAHA.116.310527","article-title":"How Common Is Residual Inflammatory Risk?","volume":"120","author":"Ridker","year":"2017","journal-title":"Circ. Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrrheum.2017.83","article-title":"The Role of IL-6 in Host Defence against Infections: Immunobiology and Clinical Implications","volume":"13","author":"Rose-John","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis--an Inflammatory Disease","volume":"340","author":"Ross","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2967\/jnumed.107.050294","article-title":"Atherosclerosis Inflammation Imaging with 18F-FDG PET: Carotid, Iliac, and Femoral Uptake Reproducibility, Quantification Methods, and Recommendations","volume":"49","author":"Rudd","year":"2008","journal-title":"J. Nucl. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.jacc.2007.05.024","article-title":"(18)Fluorodeoxyglucose Positron Emission Tomography Imaging of Atherosclerotic Plaque Inflammation Is Highly Reproducible: Implications for Atherosclerosis Therapy trialsFluorodeoxyglucose Positron Emission Tomography Imaging of Atherosclerotic Plaque Inflammation Is Highly Reproducible: Implications for Atherosclerosis Therapy Trials","volume":"50","author":"Rudd","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.smim.2013.11.002","article-title":"Interleukin-6: from Basic Biology to Selective Blockade of Pro-inflammatory Activities","volume":"26","author":"Scheller","year":"2014","journal-title":"Semin. Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1053\/j.gastro.2021.02.062","article-title":"Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1161\/ATVBAHA.111.229435","article-title":"Transsignaling of Interleukin-6 Crucially Contributes to Atherosclerosis in Mice","volume":"32","author":"Schuett","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11883-012-0246-z","article-title":"Targeting Cytokine Signaling as an Innovative Therapeutic Approach for the Prevention of Atherosclerotic Plaque Development","volume":"14","author":"Schuett","year":"2012","journal-title":"Curr. Atheroscler. Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-021-00198-1","article-title":"Targeting Inflammation in Atherosclerosis - from Experimental Insights to the Clinic","volume":"20","author":"Soehnlein","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1093\/eurheartj\/ehy862","article-title":"Persistent Arterial Wall Inflammation in Patients with Elevated Lipoprotein(a) Despite Strong Low-Density Lipoprotein Cholesterol Reduction by Proprotein Convertase Subtilisin\/kexin Type 9 Antibody Treatment","volume":"40","author":"Stiekema","year":"2019","journal-title":"Eur. Heart J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.jacc.2013.04.066","article-title":"Intensification of Statin Therapy Results in a Rapid Reduction in Atherosclerotic Inflammation: Results of a Multicenter Fluorodeoxyglucose-Positron Emission Tomography\/computed Tomography Feasibility Study","volume":"62","author":"Tawakol","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.03.003","article-title":"The Dedicated \"Lp(a) Clinic\": A Concept Whose Time Has Arrived?","volume":"300","author":"Tsimikas","year":"2020","journal-title":"Atherosclerosis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.nano.2015.02.021","article-title":"Prednisolone-containing Liposomes Accumulate in Human Atherosclerotic Macrophages upon Intravenous Administration","volume":"11","author":"van der Valk","year":"2015","journal-title":"Nanomedicine"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.jacc.2014.01.088","article-title":"Nonpharmacological Lipoprotein Apheresis Reduces Arterial Inflammation in Familial Hypercholesterolemia","volume":"64","author":"van Wijk","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"379","DOI":"10.21037\/atm.2020.02.27","article-title":"Associations between the IL-6-neutralizing sIL-6r-Sgp130 Buffer System and Coronary Artery Disease in Postmenopausal Women","volume":"8","author":"Zhou","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/cvr\/cvy191","article-title":"Interleukin 6 Trans-signalling and Risk of Future Cardiovascular Events","volume":"115","author":"Ziegler","year":"2019","journal-title":"Cardiovasc Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.758233\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T06:52:15Z","timestamp":1654757535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.758233\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":41,"alternative-id":["10.3389\/fphar.2022.758233"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.758233","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,9]]},"article-number":"758233"}}